From the FDA release "The FDA approval of CardioCel 3D is an important accomplishment for Admedus as we expand our ADAPT® tissue engineering portfolio. 3D is a pioneering new product"
From today "The Company does not consider that the FDA Grant of CardioCel® 3D itself, as opposed to the previous CardioCel® FDA clearance, is information that a reasonable person would expect to have a material effect on the price or value"
Which is it ?
Apparently when you're talking to potential investors its fantastic -when responding to an ASX please-explain, not so much.
Ann: Response to Aware Query, page-16
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
-0.380(2.42%) |
Mkt cap ! $323.4M | |||
| Open | High | Low | Value | Volume |
| $15.70 | $15.94 | $15.02 | $290.0K | 18.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280 | $15.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.57 | 779 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |